SEC 13F Intelligence

Octagon Capital Advisors LP / FDMT

Octagon Capital Advisors LP’s 4d Molecular Therapeutics In Position

Does Octagon Capital Advisors LP own 4d Molecular Therapeutics In (FDMT)? Not currently — the last reported position was 500.0K shares worth $9M in Q1 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$9M
Q1 2023
Shares
500.0K
% of Portfolio
+1.24%
Quarters Held
10
position exited

Position History FDMT

Reported value by quarter
Q4 ’20: $16MQ4 ’20Q1 ’21: $16MQ2 ’21: $20MQ2 ’21Q3 ’21: $22MQ4 ’21: $34MQ4 ’21Q1 ’22: $24MQ2 ’22: $4MQ2 ’22Q3 ’22: $4MQ4 ’22: $11MQ4 ’22Q1 ’23: $9Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2023500.0K$9M+1.24%
Q4 2022500.0K$11M+1.73%
Q3 2022500.0K$4M+0.69%
Q2 2022632.7K$4M+1.18%
Q1 20221.57M$24M+5.12%
Q4 20211.55M$34M+6.62%
Q3 2021831.3K$22M+5.52%
Q2 2021831.3K$20M+4.15%
Q1 2021378.3K$16M+6.18%
Q4 2020377.8K$16M+5.43%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of FDMT.